Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies

Louise Coppin*, Mustapha Najimi, Julie Bodart, Marie-Sophie Rouchon, Patrick van der Smissen, Stephane Eeckhoudt, Geraldine Dahlqvist, Diego Castanares-Zapatero, Mina Komuta, Sanne L. Brouns, Constance C. Baaten, Johan W. M. Heemskerk, Sandrine Horman, Nathalie Belmonte, Etienne Sokal, Xavier Stephenne

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number846
Number of pages16
JournalCells
Volume8
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • cell- and tissue-based therapy
  • liver transplantation
  • mesenchymal stem cells
  • thrombosis
  • anticoagulants
  • STEM-CELLS
  • PROCOAGULANT ACTIVITY
  • TISSUE FACTOR
  • BONE-MARROW
  • THROMBUS FORMATION
  • ACUTE DECOMPENSATION
  • TRANSPLANTATION
  • DISEASE
  • FAILURE
  • SAFETY

Cite this

Coppin, L., Najimi, M., Bodart, J., Rouchon, M-S., van der Smissen, P., Eeckhoudt, S., Dahlqvist, G., Castanares-Zapatero, D., Komuta, M., Brouns, S. L., Baaten, C. C., Heemskerk, J. W. M., Horman, S., Belmonte, N., Sokal, E., & Stephenne, X. (2019). Clinical Protocol to Prevent Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies. Cells, 8(8), [846]. https://doi.org/10.3390/cells8080846